Remdesivir N-4 intermediate
1355357-49-1
shanghai
Huateng Pharma
upon inquiry
2022-10-10
fine chemicals,peg derivatives,pharma intermediates
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
(2R,3R,4R,5R)-2-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dibenzyloxy-5-(benzyloxymethyl)tetrahydrofuran-2-carbonitrile
Other Name:1355357-49-1;(2R,3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-carbonitrile;Remdesivir N-4 intermediate;(2R,3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dibenzyloxy-5-(benzyloxymethyl)tetrahydrofuran-2-carbonitrile;MFCD32702042;SCHEMBL17712276;PTN57491;ZB1789;BS-43679;(2R,3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-bis(phenylmethoxy)-5-(phenylmethoxymethyl)oxolane-2-carbonitrile
CAS No.:1355357-49-1
Molecular Formula:C33H31N5O4
InChIKeys:PJXBLWLWNWGFJO-TXLSGFARSA-N
Molecular Weight:561.63
Exact Mass:561.238
Categories:
Characteristics-
PSA:
116.92
XLogP3:5.39798
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
fine chemicals,peg derivatives,pharma intermediates
-
Location:
Lugu Business Plaza E1,Yuelu District, Changsha City, Hunan Province
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
30
-
Total Annual Revenue:
$25 million-$50 million
-
Total Employees:
301-500
-
Year of Establishment:
2013
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
